H.R. 1492

119th CongressIn committee

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Sponsored by Gregory F. Murphy (Republican-NC-3)

Healthcare Costs & Access Healthcare & Public Health Medicare & Medicaid Pharmaceutical Policy Social Security & Retirement

Cosponsors

68

Actions

3

Roll calls

0

Amendments

0

Related bills

0

Actions

Feb 21, 2025 · Library of Congress

Introduced in House

Feb 21, 2025 · Library of Congress

Introduced in House

Feb 21, 2025 · House floor actions

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest activity

Activity

July 2026

Lobbying reported · EMD Serono · Jul 21

EMD Serono reported 2nd Quarter (Apr 1 - June 30) lobbying for EMD Serono — $700,000

BillsH.R. 1 H.R. 220 H.R. 1492 H.R. 3838 H.R. 4317 H.R. 6703 H.R. 6797 H.R. 8800 S. 832 S. 864 S. 882 S. 891 S. 1071 S. 2296 S. 3345

Lobbying reported · Biotechnology Innovation Organization · Jul 21

Biotechnology Innovation Organization reported 2nd Quarter (Apr 1 - June 30) lobbying for Biotechnology Innovation Organization — $2,360,000

Lobbying reported · Biogen · Jul 20

Biogen reported 2nd Quarter (Apr 1 - June 30) lobbying for Biogen — $1,060,000

BillsH.R. 1262 H.R. 1492 H.R. 3747 H.R. 4317 H.R. 6130 H.R. 6837 S. 832 S. 864 S. 3267 S. 3345

Lobbying reported · Bristol Myers Squibb · Jul 20

Bristol Myers Squibb reported 2nd Quarter (Apr 1 - June 30) lobbying for Bristol Myers Squibb — $3,160,000

BillsH.R. 1492 H.R. 4299 H.R. 5509 H.R. 7391 H.R. 7635

Lobbying reported · Bayer · Jul 20

Bayer reported 2nd Quarter (Apr 1 - June 30) lobbying for Bayer — $1,820,000

BillsH.R. 1492 H.R. 1897 H.R. 3160 H.R. 3269 H.R. 7366 H.R. 7567 H.R. 9171 H.R. 9260 S. 832 S. 1546 S. 1553 S. 3677 S. 3788

Lobbying reported · Dla Piper LLP (US) · Jul 20

Dla Piper LLP (US) reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $60,000

BillsH.R. 1492 H.R. 1672 S. 832

Lobbying reported · Amgen · Jul 20

Amgen reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $2,440,000

Lobbying reported · Johnson & Johnson Services · Jul 20

Johnson & Johnson Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Johnson & Johnson Services — $1,440,000

Lobbying reported · Pharmaceutical Research and Manufacturers of America (PhRMA) · Jul 20

Pharmaceutical Research and Manufacturers of America (PhRMA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $7,360,000

Lobbying reported · Soleno Therapeutics · Jul 20

Soleno Therapeutics reported 2nd Quarter (Apr 1 - June 30) lobbying for Soleno Therapeutics — $70,000

BillsH.R. 1414 H.R. 1492 H.R. 7118 S. 832

Lobbying reported · Williams And Jensen · Jul 20

Williams And Jensen reported 2nd Quarter (Apr 1 - June 30) lobbying for PhRMA — $50,000

BillsH.R. 1 H.R. 1492 S. 832

Lobbying reported · National Alliance on Mental Illness (NAMI) · Jul 20

National Alliance on Mental Illness (NAMI) reported 2nd Quarter (Apr 1 - June 30) lobbying for National Alliance on Mental Illness (NAMI) — $20,000

BillsH.R. 1 H.R. 169 H.R. 247 H.R. 438 H.R. 553 H.R. 577 H.R. 608 H.R. 912 H.R. 929 H.R. 957 H.R. 1096 H.R. 1305 H.R. 1492 H.R. 1509 H.R. 1510 H.R. 1582 H.R. 1735 H.R. 1867 H.R. 1902 H.R. 1987 H.R. 2028 H.R. 2036 H.R. 2082 H.R. 2085 H.R. 2102 H.R. 2305 H.R. 2426 H.R. 2483 H.R. 2495 H.R. 2509 H.R. 2540 H.R. 2586 H.R. 2587 H.R. 2668 H.R. 2711 H.R. 2741 H.R. 2879 H.R. 2904 H.R. 2936 H.R. 2945 H.R. 3130 H.R. 3243 H.R. 3260 H.R. 3305 H.R. 3384 H.R. 3419 H.R. 3420 H.R. 3505 H.R. 3514 H.R. 3534 H.R. 3601 H.R. 3624 H.R. 3627 H.R. 3658 H.R. 3689 H.R. 3757 H.R. 3884 H.R. 4022 H.R. 4024 H.R. 4120 H.R. 4186 H.R. 4313 H.R. 4400 H.R. 4619 H.R. 4723 H.R. 4745 H.R. 4805 H.R. 5081 H.R. 5145 H.R. 5306 H.R. 5357 H.R. 5420 H.R. 5434 H.R. 5509 H.R. 5557 H.R. 5662 H.R. 5733 H.R. 5828 H.R. 6000 H.R. 6002 H.R. 6024 H.R. 6096 H.R. 6226 H.R. 6249 H.R. 6283 H.R. 6383 H.R. 6396 H.R. 6403 H.R. 6408 H.R. 6454 H.R. 6548 H.R. 6617 H.R. 6630 H.R. 6672 H.R. 6679 H.R. 6680 H.R. 6727 H.R. 6760 H.R. 6817 H.R. 6841 H.R. 6858 H.R. 6940 H.R. 7019 H.R. 7030 H.R. 7049 H.R. 7092 H.R. 7227 H.R. 7309 H.R. 7324 H.R. 7394 H.R. 7447 H.R. 7496 H.R. 7497 H.R. 7535 H.R. 7602 H.R. 7735 H.R. 7787 H.R. 7798 H.R. 7828 H.R. 7875 H.R. 7911 H.R. 7994 H.R. 8070 H.R. 8081 H.R. 8115 H.R. 8122 H.R. 8124 H.R. 8149 H.R. 8160 H.R. 8201 H.R. 8209 H.R. 8261 H.R. 8486 H.R. 8487 H.R. 8493 H.R. 8499 H.R. 8504 H.R. 8676 H.R. 8690 H.R. 8743 H.R. 8776 H.R. 8916 H.R. 8961 H.R. 8976 H.R. 9396 H.Res. 441 H.Res. 542 H.Res. 1256 H.Res. 1290 H.Res. 1327 H.Res. 1329 S. 190 S. 219 S. 266 S. 332 S. 414 S. 473 S. 585 S. 600 S. 607 S. 609 S. 665 S. 683 S. 702 S. 752 S. 768 S. 825 S. 906 S. 921 S. 925 S. 926 S. 931 S. 942 S. 1007 S. 1056 S. 1261 S. 1477 S. 1611 S. 1655 S. 1720 S. 1748 S. 1797 S. 1816 S. 1843 S. 1878 S. 1897 S. 1912 S. 1924 S. 2131 S. 2248 S. 2282 S. 2336 S. 2446 S. 2532 S. 2556 S. 2709 S. 2825 S. 2826 S. 2847 S. 2853 S. 2903 S. 3042 S. 3139 S. 3199 S. 3271 S. 3300 S. 3431 S. 3448 S. 3461 S. 3486 S. 3521 S. 3522 S. 3690 S. 3698 S. 3714 S. 3750 S. 3783 S. 3840 S. 4001 S. 4076 S. 4149 S. 4202 S. 4210 S. 4261 S. 4288 S. 4468 S. 4481 S. 4514 S. 4552 S. 4640 S. 4754 S. 4819 S.Res. 208 S.Res. 710 S.Res. 714 S.Res. 727

Lobbying reported · Monument Advocacy · Jul 20

Monument Advocacy reported 2nd Quarter (Apr 1 - June 30) lobbying for PhRMA — $90,000

BillsH.R. 1 H.R. 1492 H.R. 7194 S. 832

Lobbying reported · Boehringer Ingelheim USA Corporation, Formerly Reported As Boehringer Ingelheim Pharmaceuticals · Jul 20

Boehringer Ingelheim USA Corporation, Formerly Reported As Boehringer Ingelheim Pharmaceuticals reported 2nd Quarter (Apr 1 - June 30) lobbying for Boehringer Ingelheim USA — $710,000

BillsH.R. 842 H.R. 1492 H.R. 7567 S. 339 S. 832

Lobbying reported · The ALS Association · Jul 20

The ALS Association reported 2nd Quarter (Apr 1 - June 30) lobbying for The ALS Association — $30,000

Lobbying reported · Avenue Solutions · Jul 20

Avenue Solutions reported 2nd Quarter (Apr 1 - June 30) lobbying for Genentech USA — $50,000

BillsH.R. 1492 H.R. 1672 H.R. 4299

Lobbying reported · Novartis · Jul 20

Novartis reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $1,410,000

Lobbying reported · Chronic Care Policy Alliance (CCPA) · Jul 20

Chronic Care Policy Alliance (CCPA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Chronic Care Policy Alliance (CCPA)

BillsH.R. 1492 H.R. 1520 H.R. 3514 H.R. 3826 H.R. 4317 H.R. 5269 H.R. 8270 H.R. 9599

Lobbying reported · Neurocrine Biosciences · Jul 20

Neurocrine Biosciences reported 2nd Quarter (Apr 1 - June 30) lobbying for Neurocrine Biosciences — $940,000

BillsH.R. 1492 H.R. 7024 H.R. 7623 S. 832

Lobbying reported · Public Citizen · Jul 20

Public Citizen reported 2nd Quarter (Apr 1 - June 30) lobbying for Public Citizen — $99,577